Delivery of interferon-β to the monkey nervous system following intranasal administration

Neuroscience

Volumn 152, Issue 3, 2008, Pages 785-797

  Thorne, R G ^a,b   Hanson, L R ^b   Ross, T M ^b   Tung, D ^b   Frey II, W H ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

Author keywords

basal ganglia; blood brain barrier; drug delivery; multiple sclerosis; olfactory system; trigeminal system

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; INTERFERON BETA SERINE; IODINE 125;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; AUTORADIOGRAPHY; BASAL GANGLION; BLOOD SAMPLING; BRAIN REGION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG TARGETING; MALE; MICRODISSECTION; MONKEY; NONHUMAN; PRIORITY JOURNAL; SPINAL CORD;

ADMINISTRATION, INTRANASAL; ANIMALS; AUTORADIOGRAPHY; BASAL GANGLIA; BLOOD-BRAIN BARRIER; BRAIN MAPPING; EXTRACELLULAR FLUID; EXTRACELLULAR SPACE; IMMUNOLOGIC FACTORS; INTERFERON-BETA; IODINE RADIOISOTOPES; MACACA; MALE; NERVOUS SYSTEM; OLFACTORY BULB; OLFACTORY MUCOSA; PROTEIN BINDING; RADIOIMMUNOASSAY; RECEPTORS, INTERFERON; TRIGEMINAL NERVE;

EID: 40949134628     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2008.01.013     Document Type: Article

References (76)

1. Adams F., Fernandez F., and Mavligit G. Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities. J Neurooncol 6 (1988) 355-359
2. Adams F., Quesada J.R., and Gutterman J.U. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA 252 (1984) 938-941
3. Balin B.J., Broadwell R.D., Salcman M., and El-Kalliny M. Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey. J Comp Neurol 251 (1986) 260-280
4. Bekisz J., Schmeisser H., Hernandez J., Goldman N.D., and Zoon K.C. Human interferons alpha, beta and omega. Growth Factors 22 (2004) 243-251
5. Benedict C., Hallschmid M., Hatke A., Schultes B., Fehm H.L., Born J., and Kern W. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 29 (2004) 1326-1334
6. Billiau A., Heremans H., Ververken D., van Damme J., Carton H., and de Somer P. Tissue distribution of human interferons after exogenous administration in rabbits, monkeys, and mice. Arch Virol 68 (1981) 19-25
7. Bino T., Edery H., Gertler A., and Rosenberg H. Involvement of the kidney in catabolism of human leukocyte interferon. J Gen Virol 59 (1982) 39-45
8. Born J., Lange T., Kern W., McGregor G.P., Bickel U., and Fehm H.L. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 5 (2002) 514-516
9. Boutros T., Croze E., and Yong V.W. Interferon-beta is a potent promoter of nerve growth factor production by astrocytes. J Neurochem 69 (1997) 939-946
10. Bradbury M.W.B., and Cserr H.F. Drainage of cerebral interstitial fluid and of cerebrospinal fluid into lymphatics. In: Johnston M.G. (Ed). Experimental biology of the lymphatic circulation (1985), Elsevier, New York 355-394
11. Bramanti P., Sessa E., Rifici C., D'Aleo G., Floridia D., Di Bella P., and Lublin F. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b. Neurology 51 (1998) 1720-1723
12. Campbell I.L., Krucker T., Steffensen S., Akwa Y., Powell H.C., Lane T., Carr D.J., Gold L.H., Henriksen S.J., and Siggins G.R. Structural and functional neuropathology in transgenic mice with CNS expression of IFN-alpha. Brain Res 835 (1999) 46-61
13. Capsoni S., Giannotta S., and Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci U S A 99 (2002) 12432-12437
14. Capuron L., and Miller A.H. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 56 (2004) 819-824
15. Chen X.-Q., Fawcett J.R., Rahman Y.-E., Ala T.A., and Frey II W.H. Delivery of nerve growth factor to the brain via the olfactory pathway. J Alzheimer Dis 1 (1998) 35-44
16. Compston A., and Coles A. Multiple sclerosis. Lancet 359 (2002) 1221-1231
17. De Rosa R., Garcia A.A., Braschi C., Capsoni S., Maffei L., Berardi N., and Cattaneo A. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci U S A 102 (2005) 3811-3816
18. During M.J., Cao L., Zuzga D.S., Francis J.S., Fitzsimons H.L., Jiao X., Bland R.J., Klugmann M., Banks W.A., Drucker D.J., and Haile C.N. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 9 (2003) 1173-1179
19. Engelhardt B., and Ransohoff R.M. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 26 (2005) 485-495
20. Frey II W.H., Liu J., Chen X., Thorne R.G., Fawcett J.R., Ala T.A., and Rahman Y.-E. Delivery of 125I-NGF to the brain via the olfactory route. Drug Deliv 4 (1997) 87-92
21. Frohman E.M., Racke M.K., and Raine C.S. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 354 (2006) 942-955
22. Gizurarson S. Animal models for intranasal drug delivery studies. Acta Pharm Nord 2 (1990) 105-122
23. Goldmann J., Kwidzinski E., Brandt C., Mahlo J., Richter D., and Bechmann I. T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa. J Leukoc Biol 80 (2006) 797-801
24. Greig N.H., Fredericks W.R., Holloway H.W., Soncrant T.T., and Rapoport S.I. Delivery of human interferon-alpha to brain by transient osmotic blood-brain barrier modification in the rat. J Pharmacol Exp Ther 245 (1988) 581-586
25. Greig N.H., Soncrant T.T., Wozniak K.M., and Rapoport S.I. Plasma and tissue pharmacokinetics of human interferon-alpha in the rat after its intravenous administration. J Pharmacol Exp Ther 245 (1988) 574-580
26. Habif D.V., Lipton R., and Cantell K. Interferon crosses blood-cerebrospinal fluid barrier in monkeys. Proc Soc Exp Biol Med 149 (1975) 287-289
27. Hall G.L., Compston A., and Scolding N.J. Beta-interferon and multiple sclerosis. Trends Neurosci 20 (1997) 63-67
28. Hartung H.P., Bar-Or A., and Zoukos Y. What do we know about the mechanism of action of disease-modifying treatments in MS?. J Neurol 251 Suppl 5 (2004) v12-v29
29. Hatterer E., Davoust N., Didier-Bazes M., Vuaillat C., Malcus C., Belin M.F., and Nataf S. How to drain without lymphatics?. Dendritic cells migrate from the cerebrospinal fluid to the B-cell follicles of cervical lymph nodes. Blood 107 (2006) 806-812
30. Hilfenhaus J., Damm H., Hofstaetter T., Mauler R., Ronneberger H., and Weinmann E. Pharmacokinetics of human interferon-beta in monkeys. J Interferon Res 1 (1981) 427-436
31. Illum L. Is nose-to-brain transport of drugs in man a reality?. J Pharm Pharmacol 56 (2004) 3-17
32. Jacobs L., Salazar A.M., Herndon R., Reese P.A., Freeman A., Jozefowicz R., Cuetter A., Husain F., Smith W.A., and Ekes R. Intrathecally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis. Results of a multicenter, double-blind study. Arch Neurol 44 (1987) 589-595
33. Jin K., Xie L., Childs J., Sun Y., Mao X.O., Logvinova A., and Greenberg D.A. Cerebral neurogenesis is induced by intranasal administration of growth factors. Ann Neurol 53 (2003) 405-409
34. Johns T.G., Kerry J.A., Veitch B.A., Mackay I.R., Tutton P.J., Tymms M.J., Cheetham B.F., Hertzog P.J., and Linnane A.W. Pharmacokinetics, tissue distribution, and cell localization of [35S]methionine-labeled recombinant human and murine alpha interferons in mice. Cancer Res 50 (1990) 4718-4723
35. Kamata M., Higuchi H., Yoshimoto M., Yoshida K., and Shimizu T. Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain. Eur Neuropsychopharmacol 10 (2000) 129-132
36. Karman J., Ling C., Sandor M., and Fabry Z. Initiation of immune responses in brain is promoted by local dendritic cells. J Immunol 173 (2004) 2353-2361
37. Kawanokuchi J., Mizuno T., Kato H., Mitsuma N., and Suzumura A. Effects of interferon-beta on microglial functions as inflammatory and antigen presenting cells in the central nervous system. Neuropharmacology 46 (2004) 734-742
38. Kosfeld M., Heinrichs M., Zak P.J., Fischbacher U., and Fehr E. Oxytocin increases trust in humans. Nature 435 (2005) 673-676
39. Liu X., Fawcett J.R., Thorne R.G., DeFor T.A., and Frey II W.H. Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. J Neurol Sci 187 (2001) 91-97
40. Liuzzi G.M., Latronico T., Fasano A., Carlone G., and Riccio P. Interferon-beta inhibits the expression of metalloproteinases in rat glial cell cultures: implications for multiple sclerosis pathogenesis and treatment. Mult Scler 10 (2004) 290-297
41. Lublin F.D., Whitaker J.N., Eidelman B.H., Miller A.E., Arnason B.G., and Burks J.S. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology 46 (1996) 12-18
42. Mackowiak P.A., Siegel E., Wasserman S.S., Cameron E., Nessaiver M.S., and Bever C.T. Effects of IFN-beta on human cerebral blood flow distribution. J Interferon Cytokine Res 18 (1998) 393-397
43. Makar T.K., Wilt S., Dong Z., Fishman P., Mouradian M.M., and Dhib-Jalbut S. IFN-beta gene transfer into the central nervous system using bone marrow cells as a delivery system. J Interferon Cytokine Res 22 (2002) 783-791
44. Malik O., Compston D.A., and Scolding N.J. Interferon-beta inhibits mitogen induced astrocyte proliferation in vitro. J Neuroimmunol 86 (1998) 155-162
45. Malucchi S., Sala A., Gilli F., Bottero R., Di Sapio A., Capobianco M., and Bertolotto A. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology 62 (2004) 2031-2037
46. Martin R.F., and Bowden D.M. Primate brain maps: structure of the macaque brain (2000), Elsevier, Amsterdam
47. Marttin E., Verhoef J.C., Cullander C., Romeijn S.G., Nagelkerke J.F., and Merkus F.W. Confocal laser scanning microscopic visualization of the transport of dextrans after nasal administration to rats: effects of absorption enhancers. Pharm Res 14 (1997) 631-637
48. Meyers C.A., Obbens E.A., Scheibel R.S., and Moser R.P. Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease. Cancer 68 (1991) 88-92
49. Meyers C.A., Scheibel R.S., and Forman A.D. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 41 (1991) 672-676
50. Noseworthy J., Miller D., and Compston A. Disease-modifying treatments in multiple sclerosis. In: Compston A., Confavreux C., Lassmann H., McDonald I., Miller D., Noseworthy J., Smith K., and Wekerle H. (Eds). McAlpine's multiple sclerosis (2006), Elsevier, Inc, Philadelphia 729-802
51. Noseworthy J.H. Progress in determining the causes and treatment of multiple sclerosis. Nature 399 (1999) A40-A47
52. Pan W., Banks W.A., and Kastin A.J. Permeability of the blood-brain and blood-spinal cord barriers to interferons. J Neuroimmunol 76 (1997) 105-111
53. Ransohoff R.M., Kivisakk P., and Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 3 (2003) 569-581
54. Reger M.A., Watson G.S., Frey II W.H., Baker L.D., Cholerton B., Keeling M.L., Belongia D.A., Fishel M.A., Plymate S.R., Schellenberg G.D., Cherrier M.M., and Craft S. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 27 (2006) 451-458
55. Reger M.A., Watson G.S., Green P.S., Wilkinson C.W., Baker L.D., Cholerton B., Fishel M.A., Plymate S.R., Breitner J.C.S., DeGroodt W., Mehta P., and Craft S. Intranasal insulin improves cognition and modulates β-amyloid in early AD. Neurology 70 (2008) 1-9
56. Ross T.M., Martinez P.M., Renner J.C., Thorne R.G., Hanson L.R., and Frey II W.H. Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. J Neuroimmunol 151 (2004) 66-77
57. Runkel L., Meier W., Pepinsky R.B., Karpusas M., Whitty A., Kimball K., Brickelmaier M., Muldowney C., Jones W., and Goelz S.E. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm Res 15 (1998) 641-649
58. Samuel M.A., and Diamond M.S. Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol 79 (2005) 13350-13361
59. Schiller J.H., Bushmeyer S.M., Ruzicka F.J., Princler G.L., Faltynek C.R., and Borden E.C. Modulation of interferon receptor expression during combination beta ser-interferon and gamma-interferon treatment of human colon carcinoma cells. Cancer Res 50 (1990) 26-31
60. Shuto H., Kataoka Y., Horikawa T., Fujihara N., and Oishi R. Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res 747 (1997) 348-351
61. Smith R.A., Kingsbury D., Alksne J., James H., and Cantell K. Distribution of interferon in cerebrospinal fluid after systemic, intrathecal, and intraventricular administration. Ann Neurol 12 (1982) 81
62. Sodoyez J.C., Sodoyez-Goffaux F.R., and Moris Y.M. 125I-insulin: kinetics of interaction with its receptors and rate of degradation in vivo. Am J Physiol 239 (1980) E3-E11
63. Sriram S., and Steiner I. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol 58 (2005) 939-945
64. Taurog A. Hormone synthesis: Thyroid iodine metabolism. In: Ingbar S.H., and Braverman L.E. (Eds). Werner's the thyroid: A fundamental and clinical text (1986), J.B. Lippincott Company, London 53-97
65. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology 45 (1995) 1277-1285
66. Thorne R.G., Emory C.R., Ala T.A., and Frey II W.H. Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res 692 (1995) 278-282
67. Thorne R.G., and Frey II W.H. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet 40 (2001) 907-946
68. Thorne R.G., Pronk G.J., Padmanabhan V., and Frey II W.H. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127 (2004) 481-496
69. Trask P.C., Esper P., Riba M., and Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol 18 (2000) 2316-2326
70. Valentine A.D., Meyers C.A., Kling M.A., Richelson E., and Hauser P. Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 25 (1998) 39-47
71. Villinger F., Brar S.S., Mayne A., Chikkala N., and Ansari A.A. Comparative sequence analysis of cytokine genes from human and nonhuman primates. J Immunol 155 (1995) 3946-3954
72. Walsh G. Biopharmaceutical benchmarks 2006. Nat Biotechnol 24 (2006) 769-776
73. Weller R.O. Pathology of cerebrospinal fluid and interstitial fluid of the CNS: significance for Alzheimer disease, prion disorders and multiple sclerosis. J Neuropathol Exp Neurol 57 (1998) 885-894
74. Weller R.O., Engelhardt B., and Phillips M.J. Lymphocyte targeting of the central nervous system: a review of afferent and efferent CNS-immune pathways. Brain Pathol 6 (1996) 275-288
75. Yokoyama S., Ohishi N., Shamoto M., Watanabe Y., and Yagi K. Isolation and expression of rat interferon beta gene and growth-inhibitory effect of its expression on rat glioma cells. Biochem Biophys Res Commun 232 (1997) 698-701
76. Yong V.W. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 59 (2002) 802-808